Immunogenicity and safety of quadrivalent inactivated influenza vaccine in children aged 6 to 35 months: A systematic review and meta-analysis

Evidence of the immunogenicity and safety of quadrivalent inactivated influenza vaccine in children aged 6 to 35 months has been emerging. To evaluate the immunogenicity and safety of quadrivalent inactivated influenza vaccine in children aged 6 to 35 months in a systematic review and meta-analysis. This meta-analysis included 12 studies with 6722 participants receiving QIV, 3575 participants receiving TIV, 4249 participants receiving full-dose QIV (F-QIV), and 3722 participants receiving half-dose QIV (H-QIV). Among children aged 6 to 35 months, QIV produces a better Immunogenicity against influenza B vaccine strains not contained in TIV. However, injection site reaction was more common for QIV, F-QIV showed superior efficacy for the B lineage, but fever and injection site pain was more frequently reported for F-QIV than H-QIV. These data support the immunogenicity and safety of quadrivalent inactivated influenza vaccine among children aged 6 to 35 months.

6至35月龄儿童接种四价灭活流感疫苗（quadrivalent inactivated influenza vaccine, QIV）的免疫原性与安全性相关证据正持续涌现。本研究旨在通过系统评价与荟萃分析，评估6至35月龄儿童接种四价灭活流感疫苗的免疫原性与安全性。本次荟萃分析共纳入12项研究，涉及6722名接种QIV的受试者、3575名接种三价灭活流感疫苗（trivalent inactivated influenza vaccine, TIV）的受试者、4249名接种全剂量四价灭活流感疫苗（full-dose QIV, F-QIV）的受试者以及3722名接种半剂量四价灭活流感疫苗（half-dose QIV, H-QIV）的受试者。在6至35月龄儿童中，QIV对TIV未覆盖的乙型流感毒株展现出更优的免疫原性。但QIV的注射部位不良反应更为常见；F-QIV对乙型流感谱系的保护效力更优，但相较于H-QIV，F-QIV报告的发热与注射部位疼痛发生率更高。上述数据证实，6至35月龄儿童接种四价灭活流感疫苗具备良好的免疫原性与安全性。